2-[[(Z)-[1-(2-Amino-4-thiazolyl)-2-(2-benzothiazolylthio)-2-oxoethylidene]amino]oxy]-acetic acid, methyl ester (CAS RN 246035-38-1

2-[[(Z)-[1-(2-Amino-4-thiazolyl)-2-(2-benzothiazolylthio)-2-oxoethylidene]amino]oxy]-acetic acid, methyl ester (CAS RN 246035-38-1

2-Propylheptanoic acid glycidyl ester, 4-methyl-2-propylhexanoic acid glycidyl ester or a mixture thereof (referred to in summary as glycidyl esters for short).

This invention provides solid oral formulations of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779).

[[4-[2-[[(3-Ethyl-2,5-dihydro-4-methyl-2-oxo-1H-pyrrol-1-yl)carbonyl]amino] ethyl]phenyl]sulfonyl]-carbamic acid ethyl ester

The compound 3,3-dimethyl-butyric acid 4-((S)-2-amino-2-methoxycarbonyl-ethyl)-2- (3,3-dimethyl-butyryloxy)-phenyl ester of formula (I) has dopaminergic properties.

This invention provides the use of rapamycin 42-ester with 3-hydroxy-2- (hydroxymethyl)-2-methylpropionic acid (CCI-779) in the treatment or inhibition of mantle cell lymphoma.

This compound is a copolymer of a 2-methyl-2-[(1-oxo-2-propenyl)amino]-1- propanesulphonic acid salt and of propenoic acid 2-hydroxyethyl ester.

The invention also relates to a process for simultaneously N(2)-acylating piperazic acid or an ester thereof and forming a bicyclic ring structure.

The preferenced acid is 2-trifluoromethyl acrylic acid.

Metabolite 490M9 = 2-[2-(4-hydroxy-2-methylphenoxymethyl)phenyl]-2-methoxy-iminoacetic acid

The most preferred compound is (4-chlorophenyl)-carbamic acid, 3-(hexahydro-3-ethyl-1-methyl-2-oxo-1H-azepin-3-yl) 2 phenyl ester.

The invention is characterized in that the fibers are contacted with a 2-cyanoacrylic acid ester during or after their production.

These analogs include DL-2-methyl-2-phthalimidinoglutaric acid and hydroxylated analogs of 2-phthalimidinoglutaric wherein each of R3 and R4 are independently H or OH.

The object is to provide a method for production of an erythro- or threo-2-amino-3-hydroxypropionic acid ester and others.